Research programme: ear and nose disorder therapeutics - Auris Medical

Drug Profile

Research programme: ear and nose disorder therapeutics - Auris Medical

Alternative Names: AM 123; AM-102 - Auris Medical

Latest Information Update: 27 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Auris Medical; Kings College London
  • Developer Auris Medical
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Nose disorders; Tinnitus

Most Recent Events

  • 23 Oct 2015 Auris Medical and King's College of London agree to co-develop AM 102 for Tinnitus
  • 15 Sep 2014 Preclinical trials in Nose disorders in Switzerland (unspecified route)
  • 15 Sep 2014 Preclinical trials in Tinnitus in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top